ABLi Therapeutics Launches To Develop Risvodetinib As Disease-Modifying Parkinson’s Therapy

ABLi Therapeutics officially launched today as a new biotech company focused on developing treatments for diseases linked to Abelson Tyrosine Kinases (c-Abl kinases). The company’s lead drug candidate, Risvodetinib (ABLi-148009), is in development as a potential disease-modifying therapy for Parkinson’s disease and related disorders. Founded by Dr. Milton H. Werner, a recognised authority on c-Abl kinases, ABLi is building on over a decade of research. 

“The largest unmet medical need for Parkinson’s patients is to halt or reverse the course of the disease. Our RAMP™ drug innovation engine facilitated the development of risvodetinib and a portfolio of novel c-Abl inhibitors that are selective for the non-receptor c-Abl kinases, have greater potency and safety than commercially marketed c-Abl kinase inhibitors, and reach therapeutic concentrations inside and outside of the brain. The c-Abl inhibitors that have emerged from our development engine have proven safety and tolerability and have shown preliminary efficacy in Parkinson's related diseases. In this endeavor, we are pleased to be supported by the distinguished members of our scientific advisory board who will assist ABLi in advancing the forefront of scientific knowledge in Parkinson’s disease and related disorders,” said Dr. Werner, Chief Executive Officer of ABLi. 

Dr Werner and his team found and pushed Risvodetinib, as well as a portfolio of second-generation compounds, which by design target c-Abl-associated disease mechanisms. ABLi’s therapeutic endeavour is aimed at chronic and systemic delivery with the aim of getting long-term effects in neurodegenerative illnesses. With the goal of enhancing patient results, the firm is setting itself at the innovative edge of c-Abl as a remedy, changing course, especially for Parkinson’s disease.